Healthcare / Medical - PharmaceuticalsUpdated 2026-05-10 22:07 UTC

FRA/GE9 stock hub

FRA/GE9 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/GE9is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

13.5B

Frankfurt Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

FRA/GE9

In the news

Latest news · FRA/GE9

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E19.2

P25 12.3P50 15.7P75 20.2

Trailing P/E18.9

P25 16.4P50 20.9P75 30.4

ROE15

P25 -6.7P50 8.5P75 17.2

ROIC10.7

P25 -1.7P50 8.5P75 17.4

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/GE9 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

221

Groups with data

Currency

USD

Showing 221 of 221 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Denmark
Country code	DE
Employees	2,973
Employees Change	46%
Employees Change Percent	1.75
Enterprise value	EUR 16.8B
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Medical - Pharmaceuticals
Isin	DK0010272202
Last refreshed	2026-05-10
Market cap	EUR 13.5B
Price	EUR 227
Price currency	EUR
Rev Per Employee	1,095,640.32x
Sector	Healthcare
Sic	2836
Symbol	fra/GE9
Website	https://www.genmab.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	5.28%
EV Earnings	23.6x
EV/EBIT	15.05x
EV/EBITDA	14.38x
EV/FCF	22.22x
EV/Sales	4.97x
FCF yield	5.61%
Forward P/E	19.16x
P/B ratio	2.74x
P/E ratio	18.94x
P/S ratio	3.99x
PE Ratio10 Y	43.38x
PE Ratio3 Y	21.58x
PE Ratio5 Y	32.49x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	32.99%
EBITDA Margin	34.09%
FCF margin	22.35%
Gross margin	93.31%
Gross Profit	EUR 3.2B
Gross Profit Growth	18.37%
Gross Profit Growth Q	23.48%
Gross Profit Growth3 Y	17.93%
Gross Profit Growth5 Y	16.39%
Net Income	EUR 712.1M
Net Income Growth	-27.73%
Net Income Growth Q	-72.82%
Net Income Growth Years	0%
Net Income Growth3 Y	2.7%
Net Income Growth5 Y	-1.41%
Pretax Margin	26.51%
Profit Margin	21.05%
Profit Per Employee	EUR 230,587
Profitable Years	13
ROA	8.48
Roa5y	10.27
ROCE	11.49
ROE	14.96
Roe5y	18.28
ROIC	10.72
Roic5y	66.47

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	6.04%
Cagr15y	25.77%
Cagr1y	26.56%
Cagr20y	10.87%
Cagr3y	-14.58%
Cagr5y	-5.78%
EPS Growth	-25.81
EPS Growth Q	-72.79
EPS Growth Years	0
EPS Growth3 Y	4.5
EPS Growth5 Y	-0.38
FCF Growth	-24.76%
FCF Growth3 Y	-1.18%
FCF Growth5 Y	0.36%
OCF Growth	-24.46%
OCF Growth Q	-98.96%
OCF Growth10 Y	32.34%
OCF Growth3 Y	-1.94%
OCF Growth5 Y	0.04%
Revenue Growth	20.66x
Revenue Growth Q	25.32x
Revenue Growth Years	0x
Revenue Growth3 Y	20.68x
Revenue Growth5 Y	18.01x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.41
Assets	EUR 10.7B
Cash	EUR 1.3B
Current Assets	EUR 2.2B
Current Liabilities	EUR 998.9M
Debt	EUR 4.6B
Debt EBITDA	EUR 3.97
Debt Equity	EUR 0.94
Debt FCF	EUR 6.14
Equity	EUR 4.9B
Interest Coverage	7.66
Liabilities	EUR 5.8B
Long Term Assets	EUR 8.6B
Long Term Liabilities	EUR 4.8B
Net Cash	EUR -3.3B
Net Cash By Market Cap	EUR -24.6
Net Debt EBITDA	EUR 2.88
Net Debt Equity	EUR 0.67
Net Debt FCF	EUR 4.39
Tangible Book Value	EUR -3.1B
Tangible Book Value Per Share	EUR -51.16

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.18
Inventory Turnover	15.82
Net Working Capital	EUR 141.4M
Quick ratio	2.17
Working Capital	EUR 1.2B
Working Capital Turnover	EUR 1.45

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	2.55%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	79.71%
1Y total return	26.54%
200-day SMA	230
3Y total return	-37.68%
50-day SMA	232.2
50-day SMA vs 200-day SMA	50over200
5Y total return	-25.76%
All Time High	445.1
All Time High Change	-48.91%
All Time High Date	2022-12-05
All Time Low	3.1
All Time Low Change	7,235.48%
All Time Low Date	2002-11-27
ATR	5.21
Ch YTD	-15.56
High	227.4
High52	303.8
High52 Date	2026-01-15
High52ch	-25.15%
Low	227.4
Low52	162.7
Low52 Date	2025-05-12
Low52ch	39.77%
Ma50ch	-2.07%
Price vs 200-day SMA	-1.12%
RSI	38.87
RSI Monthly	44.54
RSI Weekly	43.78
Sharpe ratio	0.14x
Sortino ratio	0.34
Total Return	2.55%
Tr YTD	-15.56
Tr15y	3,015.07%
Tr1m	-3.97%
Tr1w	-0.87%
Tr3m	-13.01%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 1.1B
Operating Income Growth	18.4
Operating Income Growth Q	19.68
Operating Income Growth3 Y	12.44
Operating Income Growth5 Y	3.72
Operating margin	32.99

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	60,664,302%
Net Borrowing	4,595,954,040
Shares Insiders	1.18%
Shares Institutions	60.59%
Shares Qo Q	1.17%
Shares Yo Y	-2.55%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 624.5M
Average Volume	8.9x
Bv Per Share	80.28
CAPEX	EUR -26M
Ch10y	79.71
Ch15y	3,015.1
Ch1m	-3.97
Ch1w	-0.87
Ch1y	26.54
Ch20y	687.7
Ch3m	-13.01
Ch3y	-37.68
Ch5y	-25.76
Ch6m	-7.67
Change	-2.32%
Change From Open	0
Close	232.8
Days Gap	-2.32
Depreciation Amortization	36,462,366
Earnings Date	2026-05-07
EBIT	EUR 1.1B
EBITDA	EUR 1.2B
EPS	EUR 11.37
F Score	4
FCF	EUR 756.3M
FCF EV Yield	4.5x
Financing CF	4,011,262,500
Fiscal Year End	December
Founded	1,998
Goodwill	301,026,510
Graham Number	149.80716
Graham Upside	-34.12
Income Tax	EUR 184.7M
Investing CF	-4,864,685,700
Is Primary Listing	0
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Lynch Fair Value	EUR 60.03
Lynch Upside	-73.6
Ma150	245.3
Ma150ch	-7.31%
Ma20	232.5
Ma20ch	-2.19%
Net CF	-84,995,400
Next Earnings Date	2026-08-06
Open	227.4
P FCF Ratio	17.83
P OCF Ratio	17.24
Position In Range	0
Ppne	224,709,930
Price Date	2026-05-08
Price EBITDA	EUR 11.69
Relative Volume	3.46x
Revenue	3,383,337,300x
SBC By Revenue	3.9x
Share Based Comp	131,829,600
Tax By Revenue	5.46x
Tax Rate	20.6%
Tr20y	687.67%
Tr6m	-7.67%
Z Score	2.72

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/GE9 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/GE9 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/GE9?

Insider, institutional, and short-interest positioning.

Institutional ownership

+60.6%

Share of float held by funds and institutions

Insider ownership

+1.2%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-2.6%

Negative means the company is buying back shares.

Technical

FRA/GE9 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

38.9

Neutral momentum band

Price vs 200-day MA

-1.1%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.14

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/GE9

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/GE9 stock rating?

fra/GE9 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/GE9 analysis?

The full report lives at /stocks/fra/GE9/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/GE9?

The latest report frames fra/GE9 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/GE9 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.